Will Evolus (Ticker: EOLS) Drug Be Able to Dethrone Botox?

On Friday of last week Evolus drug Jeuveau gained approval from the FDA (Food and Drug Administration) of the United States of America.

This drug will for sure be the cheaper rival of Allergan's Botox.

What does Jeuveau do? It removes wrinkle lines on the forehead and frown wrinkles. This is significant as Baby Boomers (people who are in or going to be retiring) try to retain a youthful look. No one wants to age.

I believe Allergan is in the process of suing Evolus to keep the drug off the market. However, they may not win as it has been approved and there is no patent on Botox, it is just trademarketed the name I believe.

If this drug catches on due to being the cheaper alternative, we are talking about at least a $5 billion USD company which would be 800% gain from here. Right now Botox contributes over $3.2 billion USD in revenue to Allergan in 2017. Allergan is a $45 billion USD business and just in 2015 Allergan had a $100 billion USD valuation.

We will see where this goes but it definitely is positive for Evolus. Lets see where this goes.

If you are looking to delegate Steem Power you can use BRupvoter, http://www.brupvoter.com which is one of the best upvoter bots.

Also if your looking to increase the value of one of your posts go to http://www.brupvoter.com , it always has a positive ROI at the time of vote.

You can find more articles about investing and the stock market over here http://www.thevalueswan.com

Remember this article is used for informational purposes. This document should not be regarded as investment advice or a recommendation to take action. In the event any of the assumptions used herein do not prove to be true, results are likely to vary substantially. All investments entail risks. Opinions expressed are of BrPost and http://www.thevalueswan.com . We are not liable for any damages related to this information. Consult a financial advisor before making any decisions.